Library

Displaying 1 - 25 of 2,042

Natural Disasters: Infamy vs. Nature – What Lessons Can We Learn

Natural Disasters: Infamy vs. Nature – What Lessons Can We Learn

By: Antonia Coello Novello, MD, MPH, DR.PH

Natural Disasters: Infamy vs. Nature – What Lessons Can We Learn

Natural Disasters: Infamy vs. Nature – What Lessons Can We Learn

By: Antonia Coello Novello, MD, MPH, DR.PH

Physician Leadership and the Urgency of the Moment in Medicine

Physician Leadership and the Urgency of the Moment in Medicine

By: Barbara L. McAneny, MD

Case Study

By: Gubens, Matthew

CAR-T Cell as Strategy for the Management of Hematologic Malignancies

CAR-T Cell as Strategy for the Management of Hematologic Malignancies

By: Krishna Komanduri, MD

Case Study Molecular Testing

Case Study Molecular Testing

By: Riess, Johnathan MD

Dysphasia in ALS

Dysphasia in ALS

By: Brianna Marchegiani, MS, CCC-SLP

Diagnosing ALS | Understanding ALS

Diagnosing ALS | Understanding ALS

By: Gustavo Alameda, MD, FAAN

Radiating Salivary Glands in Patients with ALS for Sialorrhea

Radiating Salivary Glands in Patients with ALS for Sialorrhea

By: Lav Goyal, MD, MBA

Caring for ALS: What I Wish I knew

Caring for ALS: What I Wish I knew

By: Melissa Alice Jones, PA

ALS Association – About Resources and Mission

ALS Association – About Resources and Mission

By: Ray Carson

National ALS Registry & Upcoming Research

National ALS Registry & Upcoming Research

By: Reshma Punjani, MPH

Changing Landscape of Therapeutic Development for Genetic ALS & All ALS

Changing Landscape of Therapeutic Development for Genetic ALS & All ALS

By: Suma Babu, MD, MPH, MBBS

Plasma Genotyping in NSCLC: Layering in the Liquid and Future Applications

Plasma Genotyping in NSCLC: Layering in the Liquid and Future Applications

By: Benjamin Levy, MD

Predictive and Prognostic Biomarkers for IO: Value of TMB, MSI, PD-L1, and Others in Liquid and Solid Tumor Specimens

Predictive and Prognostic Biomarkers for IO: Value of TMB, MSI, PD-L1, and Others in Liquid and Solid Tumor Specimens

By: Alberto Chiappori, MD

ISLB and MCM Symposia

ISLB and MCM Symposia

By: Christian Rolfo, MD, PhD, MBA, Dr.h.c, Ticiana A. Leal, MD

How to Manage Myelodysplasia: Biomarkers and Novel Treatments

How to Manage Myelodysplasia: Biomarkers and Novel Treatments

By: Guillermo Garcia-Manero, MD

Biosimilars as Front-Line Options for Cancer Care

Biosimilars as Front-Line Options for Cancer Care

By: Jorge J. García, PharmD, MS, MHA, MBA, FACHE

Biosimilars Implementation in the US: A Five Year Review

Biosimilars Implementation in the US: A Five Year Review

By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Current Status of Biosimilars and Recent Approvals

Current Status of Biosimilars and Recent Approvals

By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Novel Frontiers in the Use of ctDNA in Oncology

Novel Frontiers in the Use of ctDNA in Oncology

By: Julia Rotow, MD

Novel Frontiers in the Use of ctDNA in Oncology

Novel Frontiers in the Use of ctDNA in Oncology

By: Julia Rotow, MD

Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials

Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials

By: Paul Frankel - PhD

Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials

Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials

By: Paul Frankel, PhD

Immunotherapy in Cancer: Next Generation Biomarkers

Immunotherapy in Cancer: Next Generation Biomarkers

By: Peter Lee, MD